Добірка наукової літератури з теми "Heparin Therapeutic use"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Heparin Therapeutic use".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Heparin Therapeutic use"
Banik, Nipa, Seong-Bin Yang, Tae-Bong Kang, Ji-Hong Lim, and Jooho Park. "Heparin and Its Derivatives: Challenges and Advances in Therapeutic Biomolecules." International Journal of Molecular Sciences 22, no. 19 (September 29, 2021): 10524. http://dx.doi.org/10.3390/ijms221910524.
Повний текст джерелаMycroft-West, Courtney J., Lynsay C. Cooper, Anthony J. Devlin, Patricia Procter, Scott E. Guimond, Marco Guerrini, David G. Fernig, Marcelo A. Lima, Edwin A. Yates та Mark A. Skidmore. "A Glycosaminoglycan Extract from Portunus pelagicus Inhibits BACE1, the β Secretase Implicated in Alzheimer’s Disease". Marine Drugs 17, № 5 (16 травня 2019): 293. http://dx.doi.org/10.3390/md17050293.
Повний текст джерелаBeurskens, Danielle M. H., Joram P. Huckriede, Roy Schrijver, H. Coenraad Hemker, Chris P. Reutelingsperger, and Gerry A. F. Nicolaes. "The Anticoagulant and Nonanticoagulant Properties of Heparin." Thrombosis and Haemostasis 120, no. 10 (August 20, 2020): 1371–83. http://dx.doi.org/10.1055/s-0040-1715460.
Повний текст джерелаLudwig, Ralf. "Therapeutic Use of Heparin beyond Anticoagulation." Current Drug Discovery Technologies 6, no. 4 (December 1, 2009): 281–89. http://dx.doi.org/10.2174/157016309789869001.
Повний текст джерелаKutzner, H., and G. Hesse. "Therapeutic use of lowmolecular weight heparin for capillaritis alba." Phlebologie 37, no. 05 (2008): 259–65. http://dx.doi.org/10.1055/s-0037-1622240.
Повний текст джерелаShaughnessy, SG, E. Young, P. Deschamps, and J. Hirsh. "The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria." Blood 86, no. 4 (August 15, 1995): 1368–73. http://dx.doi.org/10.1182/blood.v86.4.1368.bloodjournal8641368.
Повний текст джерелаHoffman, Nannette B., and David J. Frohnapple. "Heparin Dosing Order Form Use in an Academic-Affiliated Veterans Affairs Medical Center." Journal of Pharmacy Technology 12, no. 6 (November 1996): 276–79. http://dx.doi.org/10.1177/875512259601200609.
Повний текст джерелаBitsadze, V. O., E. V. Slukhanchuk, J. Kh Khizroeva, M. V. Tretyakova, N. V. Pyatigorskaya, S. V. Akinshina, N. A. Makatsariya, et al. "Anticoagulant, anti-inflammatory, antiviral and antitumor properties of heparins." Obstetrics, Gynecology and Reproduction 15, no. 3 (July 9, 2021): 295–312. http://dx.doi.org/10.17749/2313-7347/ob.gyn.rep.2021.216.
Повний текст джерелаSung, Michelle, Jeanine Walenga, Walter Jeske, Omer Iqbal, and Mamdouh Bakhos. "Comparing a New Bovine Source Heparin to the Clinically Used Porcine Heparin for Platelet Function Effects and Heparin-Induced Thrombocytopenia Potential." Blood 132, Supplement 1 (November 29, 2018): 2540. http://dx.doi.org/10.1182/blood-2018-99-118781.
Повний текст джерелаOliynyk, Oleksandr, Wojciech Barg, Anna Slifirczyk, Yanina Oliynyk, Serhij Dubrov, Vitaliy Gurianov, and Marta Rorat. "Comparison of the Effect of Unfractionated Heparin and Enoxaparin Sodium at Different Doses on the Course of COVID-19-Associated Coagulopathy." Life 11, no. 10 (September 30, 2021): 1032. http://dx.doi.org/10.3390/life11101032.
Повний текст джерелаДисертації з теми "Heparin Therapeutic use"
Lim, Rebecca. "Role of interferon α and γ in the hepatic progenitor (oval) cell response". University of Western Australia. School of Medicine and Pharmacology, 2007. http://theses.library.uwa.edu.au/adt-WU2007.0081.
Повний текст джерелаDavies, Richard. "Effect of selective COX-2 inhibitors on hepatic progenitor cells and the pathologies of experimental hepatocarcinogenesis." University of Western Australia. School of Medicine and Pharmacology, 2007. http://theses.library.uwa.edu.au/adt-WU2007.0190.
Повний текст джерелаFilho, Joel Avancini Rocha. ""Efeitos da solução salina hipertônica na reperfusão hepática em pacientes submetidos ao transplante do fígado"." Universidade de São Paulo, 2006. http://www.teses.usp.br/teses/disponiveis/5/5152/tde-22032006-202604/.
Повний текст джерелаINTRODUCTION: The reperfusion phase during orthotopic liver transplantation is a critical event which sometimes promoves profound hemodynamic and cardiac changes that may be responsible for intraoperative death, multiple organ dysfunction syndrome and early graft loss. In the present study we hypothesized that the beneficial effects of hypertonic saline solution infusion during hemorrhagic shock resuscitation, considered as an ischemia and reperfusion phenomenon of the entire organism, may attenuate the hemodynamic instability that follows graft reperfusion during liver transplantation. METHODS: Thirty adult patients presenting for liver transplantation in Hospital das Clínicas of University of São Paulo Medical School were divided in two groups: Group 1 received hypertonic (7.5%) saline solution (4 mL/kg) at a rate of 20mL/min through a central line at the beginning of portal vein anastomosis; Group 2 received normal saline solution under the same conditions. Hemodynamic profiles were evaluated using mean arterial pressure, central venous pressure, pulmonary capillary wedge pressure, cardiac index and systemic vascular resistance index. Intracranial pressure study was included for those patients presenting intracranial hypertension. Data were collected at six different times: at the end of the dissection phase, at the beginning of the anhepatic phase, after the end of test solution infusion, and at 1, 5, and 30 minutes after reperfusion. Postreperfusion syndrome was defined by the occurrence of mean arterial pressure lower than 60mmHg at 1 or 5 minutes after reperfusion, and by a decrease in mean arterial pressure of more than 30% of the baseline values within the first 5 minutes after reperfusion. RESULTS: 1) Mean arterial pressure at 1 and 5 minutes after reperfusion were significantly higher in Group 1 (84.9 ± 12,33 and 77.4 ± 4.58 mmHg) than in Group 2 (62.9 ± 5.22 and 73.9 ± 3.47 mmHg), p< 0.001 and p= 0.046 respectively. 2) Postreperfusion syndrome was absent in Group 1, but present in 33.33% of patients in Group 2, p= 0.021. 3) The cardiac index increase immediately after the test solution infusion was significantly higher in Group 1 (31.27%) than in Group 2 (7.54%), p< 0.001. 4) The rise in cardiac index after reperfusion was significantly lower in Group 1 (70.42%) than in Group 2 (125.91%), p< 0.001. 5) Cardiac index at 5 and 30 minutes after reperfusion was significantly lower in Group 1 (6.51 ± 0.81 and 5.56 ± 0.86 L.min-1.m-2) than in Group 2 (7.41 ± 0.87 and 6.34 ± 0.93 L.min-1.m-2), p= 0.007 and p= 0.024 respectively. 6) When compared to their baseline moments, beginning of surgery, cardiac index at 5 and 30 minutes after reperfusion presented significantly lower increases in Group 1 (26.16% and 7.75%) than in Group 2 (45.57% and 24.80%), p = 0.019 and p = 0.021 respectively. 7) Systemic vascular resistance index immediately after the test solution infusion dropped by 18.83% in Group 1 while it increased by 9.29% in Group 2, p < 0.001. 8) The decrease in systemic vascular resistance index immediately after reperfusion was significantly lower in Group 1 (44.52%) than in Group 2 (61.80%), p < 0.001. 9) Systemic vascular resistance index at 5 and 30 minutes after reperfusion were significantly higher in Group 1 (799.35 ± 131.51 and 963.10 ± 171.33 dyn.s.cm-5.m-2) than in Group 2 (652.14 ± 115.47 and 831.47 ± 113.84 dyn.s.cm-5.m-2), p= 0.003 and p= 0.020 respectively. 10) Fluid requirements after reperfusion were significantly lower in Group 1 (12.80 ± 1.47 mL/kg/h) compared to Group 2 (15.47 ± 2.23 mL/kg/h), p= 0.001. 11) Serum sodium after the test solution infusion and at the end of surgery was significantly higher in Group 1 (152.66 ± 4.45 and 148.92 ± 3.60 mEq/L) than in Group 2 (143.59 ± 3.92 and 142.76 ± 3.17 mEq/L), p< 0.001. 12) Serum chloride after the test solution infusion and at the end of surgery was significantly higher in Group 1 (124.03 ± 4.01 and 119.41 ± 3.04 mEq/L) than in Group 2 (111.20 ± 3.80 and 111.93 ± 6.26 mEq/L), p< 0.001. 13) Blood pH immediately after the test solution infusion was significantly lower in Group 1 (7.29 ± 0.05) than in Group 2 (7.34 ± 0.06), p < 0.039. 14) In those patients with intracranial hypertension, the intracranial pressure decreased 48.77% immediately after hypertonic saline solution infusion, an effect that was sustained throughout graft reperfusion to the end of the surgical procedure. CONCLUSIONS: Hypertonic saline solution infusion during orthotopic liver transplantation abolished the postreperfusion syndrome, attenuated the hemodynamic changes secondary to graft reperfusion and lowered fluid requirements.
"Hepatic arterial embolization with A lipiodol-ethanol mixture in the cirrhotic liver: an experimental trial in an animal model." 2003. http://library.cuhk.edu.hk/record=b5891589.
Повний текст джерелаThesis (M.Phil.)--Chinese University of Hong Kong, 2003.
Includes bibliographical references (leaves 94-101).
Abstracts in English and Chinese.
Chapter 1 --- INTRODUCTION --- p.1
Chapter 2 --- HYPOTHESIS --- p.3
Chapter 3 --- OBJECTIVE --- p.4
Chapter 4 --- CLINICAL IMPLICATIONS --- p.5
Chapter 5 --- METHODOLOGY --- p.6
Chapter 5.1 --- Materials --- p.8
Chapter 5.2 --- Study method --- p.13
Chapter 5.3 --- Venues of the research --- p.22
Chapter 5.4 --- Data acquisition --- p.23
Chapter 5.5 --- Data management and analysis --- p.24
Chapter 5.6 --- Ethical considerations --- p.25
Chapter 5.7 --- Participations of persons in the research --- p.28
Chapter 6 --- RESULTS --- p.34
Chapter 6.1 --- Problems and fate of rats in the model development group --- p.34
Chapter 6.2 --- Morbidity and mortality after LEM administration --- p.38
Chapter 6.3 --- Results of radiological findings --- p.39
Chapter 6.4 --- Results of liver function tests --- p.48
Chapter 6.5 --- Results of liver morphology --- p.52
Chapter 6.6 --- Histological results --- p.53
Chapter 7 --- DISCUSSION --- p.69
Chapter 7.1 --- Problems encountered in the development group --- p.69
Chapter 7.2 --- The pilot study group --- p.71
Chapter 7.3 --- The need for the present study --- p.74
Chapter 7.4 --- LEM in cirrhotic rat compared with the normal liver rat --- p.75
Chapter 7.5 --- Liver function markers in cirrhotic liver --- p.76
Chapter 7.6 --- Discussion on the assumptions of the research --- p.80
Chapter 7.7 --- Assessment on measurement error --- p.82
Chapter 7.8 --- Errors in the pilot study --- p.83
Chapter 8 --- CONCLUSIONS --- p.84
Chapter 9 --- Future experiments that may be performed using this model --- p.85
Chapter 10 --- APPENDICES --- p.86
Chapter 10.1 --- Appendix 1: Copy on the letter of ethics approval from the Animal Research Ethics Committee of the Chinese University of Hong Kong --- p.86
Chapter 10.2 --- Appendix 2: Copy on the licences issued by the Department of Health of Hong Kong --- p.88
Chapter 11 --- REFERENCES --- p.94
Naidoo, Nalini. "A homoeopathic drug proving of Carcharhinus leucas 30CH and a subsequent comparison with that of Galeocerdo cuvier hepar 30CH." Thesis, 2018. http://hdl.handle.net/10321/3083.
Повний текст джерелаIntroduction The aim of this study was to conduct a homoeopathic proving of Carcharhinus leucas in the thirtieth centesimal potency (30CH) and to subsequently establish and describe the symptomatology in standard materia medica format and then compare this symptomatology to Galeocerdo cuvier hepar 30CH. Methodology The homoeopathic proving of Carcharhinus leucas 30CH was conducted at the Durban University of Technology and was accomplished by means of a randomised, double blind, placebo controlled trial. Carcharhinus leucas 30CH was manufactured by the researchers according to Method 6, Method 8a and 10 of the German Homoeopathic Pharmacopoeia (Benyunes, 2005: 36-39). The homoeopathic proving was conducted in the form of a double blind placebo controlled study of Carcharhinus leucas 30CH with a total of 30 healthy provers. The prover sample was divided into two groups by a process of randomisation. Twenty four provers (80%) comprised the verum group and the remaining 6 provers (20%) comprised the placebo group. The identity of the proving substance and the potency used was not disclosed to provers. Provers documented their physical, mental and emotional status for one week preceding the administration of the proving remedy. A comprehensive physical examination and case history of every prover was taken before and after the proving period. Provers were instructed to ingest one powder three times a day for two days but were told to discontinue the powders once symptoms arose. The duration of the proving spanned 6 weeks and throughout the proving process, researchers were in constant communication with all the participants. Upon completion of the proving process, journals were collected and the information therein was translated into materia medica and repertory format. This was done in order to acquire the remedy picture of Carcharhinus leucas 30CH. Thereafter, the symptomatology of Carcharhinus leucas 30CH was compared to the symptomatology of Galeocerdo cuvier hepar 30CH. Results The proving of Carcharhinus leucas 30CH produced a total of 590 already existing rubrics and 43 new rubrics. The majority of these rubrics were located in the MIND (127), GENERALS (64), HEAD (55), EXTREMITIES (50), and EYE (34). In regard to the mind, prominent features were apparent such as anger, anxiety, cheerfulness, an aversion or amelioration within company, difficulty concentrating or increased focus, varying delusions and fears and irritability. Pertaining to the head, headaches were evident with varying concomitants and modalities, with headaches predominantly affecting the forehead and sides. Sensations included dryness, heat, heaviness, perspiration and shaking. The extremities displayed symptoms primarily in the forearms, legs and thighs and sensations included paralysis, shaking, swelling and weakness. In regard to the eye, eye pain with multiple modalities were apparent, with symptoms related to the canthi and eyelids. Sensations included heat, heaviness, inflammation, itching and photophobia as well as a visible discolouration of the eye. Analysis of the results presented an understanding of the similarities and differences between Carcharhinus leucas 30CH and Galeocerdo cuvier hepar 30CH. Conclusion As hypothesised, it was evident that administering Carcharhinus leucas 30CH to healthy individuals did yield observable symptomatology. Additionally, it was apparent that various correlations between Carcharhinus leucas 30CH and Galeocerdo cuvier hepar 30CH existed
M
Книги з теми "Heparin Therapeutic use"
Barrowcliffe, Trevor W. Low molecular weight heparin. Chichester, West Sussex, England: Wiley, 1992.
Знайти повний текст джерелаKovaliv, Bohdan. Heparyn i heparynoïdy y klinichniĭ praktyt͡s︡i. Lʹviv: Lʹvivsʹkyĭ derz͡h︡avnyĭ medychnyĭ universytet im. Danyla Halyt͡s︡koho, 2003.
Знайти повний текст джерелаWarkentin, Theodore E., and Andreas Greinacher. Heparin-induced thrombocytopenia. 4th ed. New York: Informa Healthcare, 2007.
Знайти повний текст джерела1960-, Warkentin Theodore E., and Greinacher Andreas, eds. Heparin-induced thrombocytopenia. 4th ed. New York: Informa Healthcare USA, 2007.
Знайти повний текст джерелаKhaliq, Yasmin. Clinical significance of the nitroglycerin-heparin interaction. [Ottawa, Ont.?: s.n.], 1991.
Знайти повний текст джерела1960-, Warkentin Theodore E., and Greinacher Andreas, eds. Heparin-induced thrombocytopenia. 2nd ed. New York: Dekker, 2001.
Знайти повний текст джерела1960-, Warkentin Theodore E., and Greinacher Andreas, eds. Heparin-induced thrombocytopenia. 3rd ed. New York: Marcel Dekker, 2004.
Знайти повний текст джерелаThromoprophylaxis with low-molecular-weight heparins. London: Current Medicine Group, 2006.
Знайти повний текст джерела1940-, Kher André, Sarret Monique 1938-, and Toulemonde Francis 1926-, eds. Low molecular weight heparin therapy: An evaluation of clinical trials evidence. New York: Marcel Dekker, 1999.
Знайти повний текст джерелаHeparin and the prevention of atherosclerosis: Basic research and clinical application. New York: Wiley-Liss, 1990.
Знайти повний текст джерелаЧастини книг з теми "Heparin Therapeutic use"
Keeling, David. "Therapeutic anticoagulation." In Oxford Textbook of Medicine, 3018–22. Oxford University Press, 2010. http://dx.doi.org/10.1093/med/9780199204854.003.161602_update_002.
Повний текст джерелаGuedeney, Paul, Mathieu Kerneis, Johanne Silvain, Gilles Montalescot, and Jean-Philippe Collet. "Low-molecular-weight heparin." In ESC CardioMed, edited by Raffaele DeCaterina, 250–53. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198784906.003.0050.
Повний текст джерелаKeeling, David. "Therapeutic anticoagulation." In Oxford Textbook of Medicine, edited by Jeremy Dwight, 3729–34. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198746690.003.0376.
Повний текст джерелаChan, Wee, and Jeffrey Ginsberg. "Low-Molecular-Weight Heparin Use in Pregnancy." In New Therapeutic Agents In Thrombosis And Thrombolysis, Revised And Expanded. Informa Healthcare, 2002. http://dx.doi.org/10.1201/9780203909317.ch6.
Повний текст джерела"Low-Molecular-Weight Heparin Use in Pregnancy." In New Therapeutic Agents In Thrombosis And Thrombolysis, Revised And Expanded, 108–19. CRC Press, 2002. http://dx.doi.org/10.3109/9780203909317-9.
Повний текст джерелаMendoza-Torres, Evelyn, Franklin Torres, Wendy Rosales-Rada, Liliana Encinales, Lil Avendaño, María Fernanda Pérez, Ivana Terán, et al. "COVID-19 Transmission in Children: Implications for Schools." In Primary Health Care. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.99418.
Повний текст джерелаvan Mens, Thijs E., and Saskia Middeldorp. "Management of pulmonary embolism in pregnancy." In ESC CardioMed, 2786–90. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198784906.003.0665.
Повний текст джерелаVerheugt, Freek W. A. "Unfractionated heparin." In ESC CardioMed, edited by Raffaele DeCaterina, 248–50. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198784906.003.0049.
Повний текст джерелаCapodanno, Davide. "Bivalirudin and argatroban." In ESC CardioMed, edited by Raffaele DeCaterina, 255–59. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198784906.003.0052_update_001.
Повний текст джерелаAronson, J. K. "General principles of drug therapy in psychiatry." In New Oxford Textbook of Psychiatry, 1168–77. Oxford University Press, 2012. http://dx.doi.org/10.1093/med/9780199696758.003.0151.
Повний текст джерелаТези доповідей конференцій з теми "Heparin Therapeutic use"
Eldor, A., M. Bar-Ner, L. Wasserman, Y. matzner, Z. Fuks, and I. Viodavsky. "HEPARIN AND NON-ANTICOAGULANT HEPARINS INHIBIT HEPARANASE ACTIVITY IN NORMAL AND MALIGNANT CELLS:POSSIBLE THERAPEUTIC USE IN PREVENTION OF EXTRAVASATION AND DISSEMINATION OF BLOOD BORNE CELLS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643664.
Повний текст джерелаPorta, R., R. Pescador, R. Niada, M. Mantovani, and G. Prino. "FIBRINOLYTIC POTENCY OF NON ANTICOAGULANT, OXI-EEDUCED SLOW AND FAST MOVING HEPARINS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644180.
Повний текст джерелаMeschengieser, S. S., A. I. Woods, and M. Z. Lazzari. "ANTICOAGULATION IN PREGNANCY IN PATIENTS WITH CARDIAC VALVE PROSTHESIS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643266.
Повний текст джерелаSchoch, U., E. Zanetti, and A. von Felten. "PROPHYLAXIS OF THROMBOEMBOLISM DURING PREGNANCY IN THREE SISTERS WITH CONGENITAL ANTITHROMBIN III (AT m) DEFICIENCY COMBINED WITH REDUCED INDUCIBLE FIBRINOLYTIC ACTIVITY." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644363.
Повний текст джерелаRoberts, H. R. "PREVENTION OF DEEP VENOUS THROMBOSIS: CONCLUSIONS OF A CONSENSUS DEVELOPMENT CONFERENCE." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1642966.
Повний текст джерелаBroekmans, A. W., F. J. M. der Meer, and K. Briët. "TREATMENT OF CONGENITAL THROMBOTIC SYNDROMES." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643718.
Повний текст джерелаBartl, K., H. Lill, and A. Dessauer. "APPLICATION OF THE ROUTINE PHOTOMETRIC COAGULATION ASSAYS PT, APTT AND FIBRINOGEN TO A CENTRIFUGAL ANALYZER." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643257.
Повний текст джерелаFerreira, Hanna dos Santos, Agata Layanne Soares da Silva, and João Lucas de Sousa Peres. "Fibrinolytic therapy in the treatment of pediatric ischemic stroke." In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.033.
Повний текст джерелаBrien, W., M. Inwood, and K. Dillon. "QUALITY ASSURANCE OF THERAPEUTIC HEPARIN/ORAL ANTICOAGULANT THERAPY IN A GENERAL TEACHING HOSPITAL." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644170.
Повний текст джерелаFears, R. "THE EFFECT OF HEPARIN AND FIBRIN ON THE ENZYMATIC EFFICIENCIES OF THROMBOLYTICS IN_ VITRO." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643032.
Повний текст джерела